Citizens JMP lowered the firm’s price target on Acadia Pharmaceuticals (ACAD) to $37 from $39. Acadia reported Q4 financial results largely consistent with consensus estimates and provided 2025 guidance, the analyst tells investors in a research note. NUPLAZID continued to demonstrate strong performance and is well positioned to grow meaningfully for several years, and beyond the commercial franchises, Citizens JMP sees multiple opportunities for pipeline programs to drive long-term value, and strong cash flow provides leverage both to invest internally and look to acquire additional assets.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- Positive Outlook for ACADIA Pharmaceuticals: Strategic Growth and Promising Metrics Drive Buy Rating
- Optimistic Growth Outlook for ACADIA Pharmaceuticals: Buy Rating Affirmed by Tessa Romero
- Promising Growth Trajectory and Strategic Investments Drive Buy Rating for ACADIA Pharmaceuticals
- Acadia Pharmaceuticals Reports Strong 2024 Financial Results
- ACADIA Pharmaceuticals: Strong Financial Performance and Growth Prospects Justify Buy Rating